Skip to main content

SU5416 (Semaxinib) | Flk-1/KDR inhibitor

$129.00
SKU:
C7541-5
Adding to cart… The item has been added

SU5416 (Semaxinib) is a reversible, ATP-competitive, oxindole-based inhibitor of Flk-1/KDR receptor tyrosine kinase. SU5416 inhibits VEGF-dependent phosphorylation of the Flk-1 receptor in Flk-1-overexpressing NIH 3T3 cells with a IC50 of 1.04 uM. In an ELISA-based assay, SU5416 inhibits autophosphorylation of the Flk-1 receptor at an IC50 of 1.23 uM. [1]

In a mitogenic/proliferation assay in HUVECs, the IC50 of SU5416 is extremely time-dependent, ranging from 1 uM to 40 nM at 48h incubation. These data in conjunction with dose-ranging studies support regimens of less than once-daily dosing of SU5416. [2]

More recent studies have shown that SU5416 is also an agonist of the aryl hydrocarbon receptor (AHR), leading to the generation of regulatory T-cells in vitro. SU5416 also upregulates CYP1A1 and CYP1B1. [3]


Technical information:

Chemical Formula:   C15H14N2O
CAS #:   204005-46-9
Molecular Weight:   238.28
Purity: > 98%
Appearance:   White
Chemical Name:   2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)
Solubility:   Up to 20 mM in DMSO
Synonyms:   SU5416, SU 5416, su-5416, Semaxinib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. Fong et al., SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types. Cancer Res. 1999, 59, 99-106. Pubmed ID: 9892193
2. Mendel et al., The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function. Clin. Cancer Res. 2000, 6, 4848-4858. Pubmed ID: 11156244
3. Mezrich et al., SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation. PLOS One, 2012, 7(9), e44547.

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.